To: Afaq Sarwar who wrote (2584 ) 1/13/1998 11:23:00 AM From: Gary Korn Read Replies (2) | Respond to
(COMTEX) Harvard Scientific Reports Scientific Breakthrough for its P
Harvard Scientific Reports Scientific Breakthrough for its Patented Lyophilized
Liposomal PGE-1 Treatment for Male Erectile Dysfunction
RENO, NEV. (Jan. 13) BW HEALTHWIRE -Jan. 13, 1998--Harvard Scientific
Corp. (OTC BB:HVSF) a Nevada corporation, announced Tuesday that it has
made a patented breakthrough in the stability of Prostaglandin E-1.
With the assistance of Pyramid Labs in Costa Mesa, Calif., a stability
study of Harvard Scientific's lyophilized liposomal Prostaglandin E-1
has proven it to be stable at room temperature for at least 6-months.
Dr. Darryl See, the project manager and a company consultant stated:
"All prior intrameatal Prostaglandin E-1 treatment products have
required refrigeration for long term stability. This includes
refrigeration of product during manufacturing, shipping, storage in the
pharmacy and while in the hands of the patient. This is a very
cumbersome and costly procedure. At this time, we are conducting
additional stability studies to determine the exact shelf-life at room
temperature."
Medhat Gorgy, president of Pyramid Labs stated: "The stability study
data for Harvard Scientific's lyophilized liposomal product confirms
that the product is stable at room temperature for a minimum of
6-months. In addition, the most recent results indicate that the
product shows promise for an extended shelf life at room temperature
beyond the previous room temperature shelf-life projections of
6-months."
Thomas Waite, president and CEO added: "The results of this stability
study, conducted by Dr. See and Mr. Gorgy, provides the company a
unique advantage over other intrameatal Prostaglandin E-1 treatments
for male erectile dysfunction. The company's patented process does not
rely on refrigeration and will provide the convenience of dry storage
to pharmacies, physicians and patients. Also, a positive impact to the
company's cash flow should be realized, due to savings in cost of
manufacturing and product storage, throughout the clinical trials and
as the company ramps-up for marketing the product after FDA approval.
These same savings, associated with the costs of manufacturing and
distribution, should provide a less expensive product for the patient
and contribute positively to the company's gross margins."
Harvard Scientific Corp. is a biopharmaceutical company that develops
products relating to liposomal delivery of Prostaglandin E-1 for the
treatment of male erectile dysfunction, impotency and sexual
enhancement. The company's patented process allows the Prostaglandin
E-1 to be administered as a liquid via a painless delivery system. The
company also has developed a topically applied skin treatment for
psoriasis and is working with the FDA to establish Phase I clinical
trials protocol for that product.
Prostaglandin E-1 is a naturally occurring vasodilator originally
approved by the U.S. FDA for intravenous infusion in neonates. In
1995, PGE-1 was approved by the FDA as a treatment for male erectile
dysfunction for Upjohn's Caverject(r), which is administered by needle
injection. In November 1996, Vivus Inc.'s MUSE(r) delivery system was
approved by the FDA. The company believes that its product represents
a tremendous treatment advantage over other delivery systems currently
being utilized in the industry.
-0- cp/mi*
CONTACT: I.W. Miller & Co.
Ira Miller, 714/833-9001
or
Scopes, Garcia & Carlisle
Ellie Muth, 801/364-8720
or
Martin E. Janis & Co.
Hal Schweig, 312/943-1100
KEYWORD: NEVADA INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
*** end of story ***
